Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin Add-on to Insulin Background Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus prior to informed consent.~* Chinese male or female patients who are pre-treated with insulin alone or in combination with metformin:~  * With maximum insulin dose of \<= 1 unit/kg/day. Acceptable basal insulins could be insulin glargin, insulin detemir or NPH (neutral protamin hagedorn) insulin with duration of action up to 24 h; acceptable pre-mixed insulins could be preparations with 25/75 or 30/70 ratio, with once or twice daily posology only. The total insulin dose should not be changed by more than 10% of the baseline value within the 12 weeks prior to randomisation (Visit 3). Both human insulin \& insulin analogue are accepted.~ * If the patient is taking metformin, stable dose (at least 1500 mg daily) must be maintained for at least 12 weeks without dose adjustments prior to randomisation (Visit 3).~* HbA1c fulfills the following criteria: \>= 7.5 % to \<= 10.0 % at Visit 1.~* Age \>= 18 years at Visit 1.~* BMI \<= 45 kg/m2 (Body Mass Index) at Visit 1.~* Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH (International Conference on Harmonisation) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.~  * A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile.~ * Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.~* Signed and dated written informed consent by date of Visit 1 in accordance with ICH-GCP (Good Clinical Practice) and local legislation~Exclusion criteria:~* Uncontrolled hyperglycaemic with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day).~* Any other antidiabetic drug within 3 months prior to informed consent except those defined as background treatment via inclusion criterion 2.~* Acute coronary syndrome (non-STEMI (ST Segment Elevation Myocardial Infarction), STEMI and unstable angina pectoris), stroke or TIA (Transient ischemic attack) within 3 months prior to informed consent.~* Indication of liver disease, defined by serum levels of either ALT (Alanine aminotransferase) (SGPT (serum glutamic pyruvate transaminase )), AST (Aspartate aminotransferase) (SGOT (serum glutamic-oxaloacetic transaminase)), or alkaline phosphatase above 3 × upper limit of normal (ULN (upper limit of normal)) as determined during screening and/or run-in phase.~* Any contraindications to metformin according to the local label for those patients that enter the study with metformin therapy as provided in ISF (Investigator Site File).~* Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption.~* Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.~* Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia).~* Known hypersensitivity or allergy to the investigational product or its recipients.~* Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.~* Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM (Type 2 diabetes mellitus).~* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.~* Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.~* Participation in another trial with an investigational drug within 2 months prior to informed consent or previous enrolment in this trial.~* Any other clinical condition that would jeopardize patient's safety while participating in this clinical trial in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- linagliptin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).